Menu
← Oncology Approval Tracker
FDA DECISION ·
Besremi
ropeginterferon alfa-2b-njft · PharmaEssentia
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with polycythemia vera.
LAMPGEN ANALYSIS
Why it matters
The action adds a long-acting interferon option for a chronic myeloproliferative neoplasm.
What research teams should watch
Track hematocrit and phlebotomy timing across visits and reconcile dose titration.
PRIMARY RECORDS